(NASDAQ: CRIS) Curis's forecast annual revenue growth rate of 65.05% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.12%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.11%.
Curis's revenue in 2026 is $9,443,000.On average, 7 Wall Street analysts forecast CRIS's revenue for 2026 to be $499,213,939, with the lowest CRIS revenue forecast at $450,559,870, and the highest CRIS revenue forecast at $558,302,448. On average, 6 Wall Street analysts forecast CRIS's revenue for 2027 to be $833,395,834, with the lowest CRIS revenue forecast at $458,395,694, and the highest CRIS revenue forecast at $1,721,082,734.
In 2028, CRIS is forecast to generate $1,828,225,631 in revenue, with the lowest revenue forecast at $881,530,181 and the highest revenue forecast at $3,400,187,840.